Apollomics, Inc. (APLM)

Market Cap	48.42M -38.4%
Revenue (ttm)	8.84M +776.3%
Net Income	-10.94M
EPS	-7.57
Shares Out	2.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	347
Open	21.77
Previous Close	22.05
Day's Range	20.49 - 23.39
52-Week Range	10.01 - 36.53
Beta	1.54
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 27, 2026

About APLM

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 14
• Stock Exchange: Nasdaq
• Ticker Symbol: APLM
• Website: https://www.apollomicsinc.com

Financial Performance

In 2025, Apollomics's revenue was $8.84 million, an increase of 776.31% compared to the previous year's $1.01 million. Losses were -$10.94 million, -79.69% less than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 20, 2026

Data Sources Report a data error